Prasugrel could be the “first choice” P2Y12 inhibitor recommendation in routine care after coronary stenting in patients with acute coronary syndromes (ACS), investigators in the SWITCH SWEDEHEART study say, after finding that prasugrel has less major bleeding risk versus ticagrelor.